How to manage hyperthyroid disease in pregnancy

Uncontrolled hyperthyroidism can be fairly innocuous or life-threatening to mother and fetus

CASE Life on the line

A 32-year-old woman in the 24th week of her fourth pregnancy arrives at the emergency department complaining of cough and congestion, shortness of breath, and swelling in her face, hands, and feet. The swelling has become worse over the past 2 weeks, and she had several episodes of bloody vomiting the day before her visit. The patient says she has not experienced any leakage of fluid, vaginal bleeding, or contractions. She reports good fetal movement.

The patient’s medical history is unremarkable, but a review of systems reveals a 15-lb weight loss over the past 2 weeks, racing heart, worsening edema and shortness of breath, and diarrhea.

Physical findings include exophthalmia and an enlarged thyroid with a nodule on the right side, as well as bilateral rales, tachycardia, tremor, and increased deep tendon reflexes. There is no evidence of fetal cardiac failure or goiter.

A computed tomography (CT) scan of the mother shows bilateral pleural effusions indicative of high-output cardiac failure. Thyroid ultrasonography (US) reveals a diffusely enlarged thyroid gland with a right-sided mass.

The thyroid-stimulating hormone (TSH) level is undetectable. Fetal heart rate is in the 160s, with normal variability and occasional variable deceleration. Fetal US is consistent with the estimated gestational age and shows adequate amniotic fluid and no gross fetal anomalies.

What is the likely diagnosis?

This is a classic example of undiagnosed hyperthyroidism in pregnancy manifesting as thyroid storm.

As the case illustrates, uncontrolled hyperthyroidism in pregnancy poses a significant challenge for the obstetrician. The condition can cause miscarriage, preterm delivery, intrauterine growth restriction, preeclampsia, and—at its most dangerous—thyroid storm.1 Thyroid storm is a life-threatening emergency, and treatment must be initiated even before hyperthyroidism is confirmed by thyroid function testing.2 The good news is that these complications can be successfully avoided with adequate control of thyroid function.

Overt hyperthyroidism, seen in 0.2% of pregnancies, requires active intervention to avert adverse pregnancy outcome and neurologic damage to the fetus. Subclinical disease, seen in 1.7% of pregnancies, can also create serious obstetrical problems.1

The effects of hyperthyroidism in pregnancy vary in severity, ranging from the fairly innocuous, transient, and self-limited state called gestational transient thyrotoxicosis to the life-threatening emergency of hyperthyroidism.2

The authors report no financial relationships relevant to this article.

IN THIS ARTICLE

- Uncontrolled hyperthyroidism: Serious consequences
  Page 24
- Stepwise management of thyroid storm
  Page 27

Annette E. Bombrys, DO
Dr. Bombrys is a Fellow in Maternal–Fetal Medicine, Department of Obstetrics and Gynecology, at the University of Cincinnati College of Medicine in Cincinnati, Ohio.

Mounira A. Habli, MD
Dr. Habli is a Fellow in Maternal–Fetal Medicine, Department of Obstetrics and Gynecology, at the University of Cincinnati College of Medicine in Cincinnati, Ohio.

Baha M. Sibai, MD
Dr. Sibai is Professor, Department of Obstetrics and Gynecology, at the University of Cincinnati College of Medicine in Cincinnati, Ohio.

www.obgmanagement.com

February 2008 • OBG MANAGEMENT

For mass reproduction, content licensing and permissions contact Dowden Health Media.
Hyperthyroidism

**TABLE 1**

<table>
<thead>
<tr>
<th>Thyroid-Stimulating Hormone</th>
<th>Free Tri-iodothyronine</th>
<th>Free Thyroxine</th>
<th>Total Tri-iodothyronine</th>
<th>Total Thyroxine</th>
<th>Then the Mother's Condition Is ...</th>
</tr>
</thead>
<tbody>
<tr>
<td>No change</td>
<td>No change</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Pregnancy</td>
</tr>
<tr>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>Hyperthyroidism</td>
</tr>
<tr>
<td>↓</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
<td>No change</td>
<td>Subclinical hyperthyroidism</td>
</tr>
</tbody>
</table>

**TABLE 2**

Causes of hyperthyroidism in pregnancy

- Graves' disease
- Adenoma
- Toxic nodular goiter
- Thyroiditis
- Excessive thyroid hormone intake
- Choriocarcinoma
- Molar pregnancy

Pregnant women who have a history of high-dose neck radiation, thyroid therapy, postpartum thyroiditis, or an infant born with thyroid disease should also be tested at the first prenatal visit.

**Telltale signs and laboratory tests**
The signs and symptoms of hyperthyroidism can include nervousness, heat intolerance, tachycardia, palpitations, goiter, weight loss, thyromegaly, exophthalmia, increased appetite, nausea and vomiting, sweating, and tremor. The difficulty here? Many of these symptoms are also seen in pregnant women who have normal thyroid function, so that symptoms alone are not a reliable guide.

Instead, the diagnosis of overt hyperthyroidism is made on the basis of laboratory tests indicating suppressed TSH and elevated levels of free thyroxine (FT₄) and free triiodothyronine (FT₃). Subclinical hyperthyroidism is defined as a suppressed TSH level with normal FT₄ and FT₃ levels.

The effects of hyperthyroidism on laboratory values are shown in **TABLE 1**. A form of hyperthyroidism called the T₃— TOXICOSIS SYNDROME IS DIAGNOSED BY SUPPRESSED TSH, NORMAL FT₄, AND ELEVATED FT₃ LEVELS.

**What are the causes?**
The most common cause of hyperthyroidism in pregnancy—accounting for some 95% of cases—is Graves' disease.
This autoimmune disorder is characterized by autoantibodies that activate the TSH receptor. These autoantibodies cross the placenta and can cause fetal and neonatal thyroid dysfunction even when the mother herself is in a euthyroid condition.

Far less often, hyperthyroidism in pregnancy has a cause other than Graves’ disease; TABLE 2 summarizes the possibilities. Other causes of hyperthyroidism in early pregnancy include choriocarcinoma and gestational trophoblastic disease (partial and complete moles) (TABLE 3).

**Signs and symptoms of Graves’ disease**

Women who have Graves’ disease usually have thyroid nodules and may have exophthalmos, pretibial myxedema, and tachycardia. They also display other classic signs and symptoms of hyperthyroidism, such as muscle weakness, tremor, and warm and moist skin.

During pregnancy, Graves’ disease usually becomes worse during the first trimester and postpartum period; symptoms resolve during the second and third trimesters.

**Thyrototoxic receptor and antithyroid antibodies**

Antithyroid antibodies are common in patients with autoimmune thyroid disease, as a response to thyroid antigens. The two most common antithyroid antibodies are thyroglobulin and thyroid peroxidase (anti-TPO). Anti-TPO antibodies are associated with postpartum thyroiditis and fetal and neonatal hyperthyroidism. TSH-receptor antibodies include thyroid-stimulating immunoglobulin (TSI) and TSH-receptor antibody. TSI is associated with Graves’ disease. TSH-receptor antibody is associated with fetal goiter, congenital hypothyroidism, and chronic thyroiditis without goiter.

**Who do you test for antibodies?** Test for maternal thyroid antibodies in patients who:

- had Graves’ disease with fetal or neonatal hyperthyroidism in a previous pregnancy
- have active Graves’ disease being treated with antithyroid drugs
- are euthyroid or have undergone ablative therapy and have fetal tachycardia or intrauterine growth restriction
- have chronic thyroiditis without goiter
- have fetal goiter on ultrasound.

Newborns who have congenital hyperthyroidism should also be screened for thyroid antibodies.

**What are the consequences?**

Hyperthyroidism can have multiple effects on the pregnant patient and her fetus, ranging in severity from the minimal to the catastrophic.

**Gestational transient thyrotoxicosis**

This condition is presumably related to high levels of human chorionic gonadotropin, a substance known to stimulate TSH receptors. Unhappily for your patient, the condition is usually heralded by severe bouts of nausea and vomiting starting at 4 to 8 weeks’ gestation. Laboratory tests show significantly elevated levels of FT$_4$ and FT$_3$ and suppressed TSH. Despite this significant derangement, patients generally have no evidence of a hypermetabolic state.

This condition resolves by 14 to 20 weeks of gestation, is not associated with poor pregnancy outcomes, and does not require treatment with antithyroid medication.

---

**TABLE 3**

<table>
<thead>
<tr>
<th>What causes severe hyperthyroidism before 20 weeks’ gestation?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gestational transient thyrotoxicosis</strong></td>
</tr>
<tr>
<td><strong>Choriocarcinoma</strong></td>
</tr>
<tr>
<td><strong>Gestational trophoblastic disease</strong></td>
</tr>
<tr>
<td>• Partial hydatidiform mole</td>
</tr>
<tr>
<td>• Complete hydatidiform mole</td>
</tr>
</tbody>
</table>

---

**FAST TRACK**

The most common cause of hyperthyroidism in pregnancy is Graves’ disease, which accounts for about 95% of cases.
Hyperthyroid disease in pregnancy

**FIGURE 1**

Consequences of uncontrolled hyperthyroidism

<table>
<thead>
<tr>
<th>Complications of pregnancy</th>
<th>Percentage of affected pregnancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preeclampsia</td>
<td>35</td>
</tr>
<tr>
<td>Heart failure</td>
<td>30</td>
</tr>
<tr>
<td>Preterm delivery (PTD)</td>
<td>25</td>
</tr>
<tr>
<td>Fetal growth restriction (FGR)</td>
<td>20</td>
</tr>
<tr>
<td>Stillbirth</td>
<td>15</td>
</tr>
</tbody>
</table>

Several studies have found a much higher risk of pregnancy complications in women who have uncontrolled hyperthyroidism, compared with their treated and euthyroid peers.azy

PTD = preterm delivery; FGR = fetal growth restrictions.

---

**Adverse pregnancy outcomes**

Pregnant women who have uncontrolled hyperthyroidism are at increased risk of spontaneous miscarriage, congestive heart failure, preterm delivery, intrauterine growth restriction, and preeclampsia. Studies that evaluated pregnancy outcomes in 239 women with overt hyperthyroidism showed increased risk of adverse pregnancy outcomes, compared with treated, euthyroid women (**FIGURE 1**).azy

**Fetal and neonatal hyperthyroidism**

Hyperthyroidism in the fetus or newborn is caused by placental transfer of maternal immunoglobulin antibodies (TSI) to the fetus and is associated with maternal Graves’ disease. The incidence of neonatal hyperthyroidism is less than 1%. It can be predicted by rising levels of maternal TSI antibodies, to the point where levels in the third trimester are three to five times higher than they were at the beginning of pregnancy.4

Fetal hyperthyroidism develops at about 22 to 24 weeks’ gestation in mothers with a history of Graves’ disease who have been treated surgically or with ablative therapy prior to pregnancy. Even when these therapies achieve a euthyroid state in the mother, TSI levels may remain elevated and lead to fetal hyperthyroidism.

Characteristics of hyperthyroidism in the fetus include tachycardia, intrauterine growth restriction, congestive heart failure, oligohydramnios, and goiter. Treating the mother with antithyroid medications will ameliorate symptoms in the fetus.5

**Thyroid storm**

This is the worst-case scenario—a rare but potentially lethal complication of uncontrolled hyperthyroidism. Thyroid storm is a hypermetabolic state characterized by fever, nausea, vomiting, diarrhea, tachycardia, altered mental status, restlessness, nervousness, seizures, coma, and cardiac arrhythmias. It occurs in 1% to 2% of patients receiving thioamide therapy.6

In most instances, thyroid storm is a complication of uncontrolled hyperthyroidism, but it can also be precipitated by infection, surgery, thromboembolism, preeclampsia, labor, and delivery.

**Thyroid storm is a medical emergency**

This manifestation of uncontrolled hyperthyroidism is so urgent that treatment should be initiated before the results of TSH, FT, and FT tests are available.7 Delivery should be avoided, if possible, until the mother’s condition can be stabilized but, if the status of the fetus is compromised, delivery is indicated.

Treatment of thyroid storm begins with stabilization of the patient, followed by initiation of a stepwise management approach (**FIGURE 2**, page 27).

**Treatment of hyperthyroidism in pregnancy**

Two medications are available to treat hyperthyroidism in pregnancy: propylthiouracil (PTU) and methimazole. These medications are known as thioamides.8

---

**FAST TRACK**

Thyroid storm can be precipitated by infection, surgery, thromboembolism, preeclampsia, labor, and delivery.
PTU blocks the oxidation of iodine in the thyroid gland, thereby preventing the synthesis of T₄ and T₃. The initial dosage for hyperthyroid women who are not pregnant is usually 300 to 450 mg/day in three divided doses every 8 hours, and this dosing strategy can also be applied to the pregnant patient. Maintenance therapy is usually achieved with 100 to 150 mg/day in divided doses every 8 to 12 hours.⁹

Methimazole works by blocking the organification of iodide, which decreases thyroid hormone production. The usual dosing, given in three divided doses every 8 hours, is 15 mg/day for mild hyperthyroidism, 30 to 40 mg/day for moderately severe hyperthyroidism, and 60 mg/day for severe hyperthyroidism. Maintenance therapy with methimazole is usually given at a dosage of 5 to 15 mg/day.⁹

In the past, PTU was considered the drug of choice for treatment of hyperthyroidism in pregnancy because clinicians believed it crossed the placenta to a lesser degree than did methimazole, and because methimazole was associated with fetal esophageal and choanal atresia and fetal cutis aplasia (congenital skin defect of the scalp).¹,² Available evidence does not, however, support these conclusions.³,⁴ Whatever medication regimen you choose, thyroid function should be monitored 1) every 4 weeks until TSH and FT₄ levels are within normal limits and 2) every trimester thereafter. FIGURE 3 (page 31) presents an algorithm for managing hyperthyroidism in pregnancy.

**CASE Resolved**

The patient in thyroid storm described at the beginning of this article requires aggressive management, as outlined in the algorithm in FIGURE 2. As her symptoms diminish, fetal tachycardia resolves. The patient’s FT₄ level begins to decline, consistent with appropriate treatment, and she is discharged home and instructed to continue PTU and

**FIGURE 2**

Management of thyroid storm

1. Stabilize patient
   - Airway, breathing, circulation (ABCs)

2. Give propylthiouracil (PTU), 600 to 800 mg orally followed by 150 mg every 4 to 6 hours (methimazole is an alternative if oral administration of PTU is impossible)
   - 1–2 hours after administering PTU, give:
     - Potassium iodide, 2–5 drops orally every 8 hours, or
     - Lugol’s solution, 8 drops every 6 hours, or
     - Sodium iodide, 0.5–1.0 g intravenously (IV) every 8 hours
   - Immediately initiate dexamethasone, 2 mg IV or intramuscularly every 6 hours, for 24 hours (4 doses)
   - Immediately initiate propranolol, 20–80 mg orally every 4–6 hours, or
     - 1–2 mg IV every 5 minutes, until a total of 6 mg, then 1–10 mg IV every 4 hours
   - Give phenobarbital, 30–60 mg orally every 6–8 hours, as needed for agitation and restlessness

Aggressive management of thyroid storm is indicated, following a stepwise approach. Each medication used to treat thyroid storm plays a specific role in suppressing thyroid function. Propylthiouracil (PTU) blocks additional synthesis of thyroid hormone and inhibits the conversion of thyroxine (T₄) to triiodothyronine (T₃). Methimazole blocks additional synthesis of thyroid hormones. Saturated solution of potassium iodide (SSKI), Lugol’s solution, and sodium iodide block the release of thyroid hormone from the gland. Dexamethasone is used to decrease thyroid hormone release and peripheral conversion of T₄ to T₃. Propranolol is used to treat maternal tachycardia by inhibiting the adrenergic effects of excessive thyroid hormones. Finally, phenobarbital is used to treat maternal agitation and restlessness caused by the increased catabolism of thyroid hormones.

SOURCE: Adapted from ACOG.²

**FAST TRACK**

Whatever regimen you select to treat hyperthyroidism of pregnancy, adopt a program of close monitoring of thyroid function.

CONTINUED
labetalol and to follow up at the endocrinology and high-risk obstetrics clinics as soon as possible.

The patient does not follow this advice. Consequently, she presents at 33 5/7 weeks in a hypertensive crisis, with symptoms similar to those she first exhibited plus acute pulmonary edema. Fetal heart rate is initially in the 130s, with good variability and occasional decelerations (FIGURE 4A), but decelerations then become worse (FIGURE 4B) and emergency cesarean section is performed.

A male infant is delivered, weighing 2,390 g. Apgar scores are 0 at 1 minute and 9 at 5 minutes. A 25% placental abruption is noted at the time of delivery.

Mother and fetus are stabilized and discharged.■

References

Fetal heart rate is initially in the 130s with good variability and occasional decelerations (A), but then deteriorates, with increasing decelerations (B), an indication for immediate delivery.